Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q3 2022 vs. Q2 2022
How the institutions holding Alvotech changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 17 | 14 | −3 |
| Shares | 19.4M | 20.8M | +1.35M (+7.0%) |
| Value | $157.8M | $140.6M | −$17.2M (−10.9%) |
New holders (1)
Institutions that held Alvotech at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alyeska Investment Group, L.P. | 463,320 | $3.13M | 0.04% |
Sold out (4)
Institutions that held Alvotech at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Millennium Management LLC | 52,442 | $431.0K |
| Jane Street Group, LLC | 41,060 | $337.0K |
| Penserra Capital Management LLC | 2,639 | $21.0K |
| Barclays PLC | 1,256 | $10.0K |